Warren J D, Schott J M, Fox N C, Thom M, Revesz T, Holton J L, Scaravilli F, Thomas D G T, Plant G T, Rudge P, Rossor M N
Dementia Research Centre, Institute of Neurology, London, UK.
Brain. 2005 Sep;128(Pt 9):2016-25. doi: 10.1093/brain/awh543. Epub 2005 May 18.
Brain biopsy has an uncertain role in the diagnosis of dementia. Here we report a retrospective analysis of 90 consecutive cerebral biopsies undertaken for the investigation of dementia in adults at a tertiary referral centre between 1989 and 2003. In most cases (90%), biopsy consisted of a right frontal full thickness resection of cortex, white matter and overlying leptomeninges. Fifty-seven per cent of biopsies were diagnostic: the most frequent diagnoses were Alzheimer's disease (18%), Creutzfeldt-Jakob disease (12%) and inflammatory disorders (9%). Other diagnoses in individual patients included Pick's disease, corticobasal degeneration and other tauopathies, Lewy body dementia, multiple sclerosis, Whipple's disease, progressive multifocal leucoencephalopathy, cerebral autosomal dominant arteriopathy with subcortical ischaemic leucoencephalopathy, vasculopathies and paraneoplastic encephalopathy. The most frequent biopsy finding in the non-diagnostic group and for the series as a whole (37%) was non-specific gliosis variably affecting both cortex and white matter. Complications (11%) included seizures, intracranial and wound infections, and intracranial haemorrhage; there were no deaths or lasting neurological sequelae attributable to the procedure. No trends in diagnostic yield or complication rate over the course of the series were identified. Information obtained at biopsy determined treatment in 11%. A raised cerebrospinal fluid cell count was the only robust predictor of a potentially treatable (inflammatory) process at biopsy. The constellation of behavioural change, raised CSF protein and matched oligoclonal bands in CSF and serum was associated with non-specific gliosis at biopsy. This series underlines the value of cerebral biopsy in the diagnosis of dementia, and suggests that certain clinical and laboratory features may be useful in guiding the decision to proceed to brain biopsy where a treatable disease cannot be excluded by other means.
脑活检在痴呆症诊断中的作用尚不明确。在此,我们报告了一项回顾性分析,该分析涉及1989年至2003年间在一家三级转诊中心对90例连续进行的成人痴呆症调查脑活检。在大多数病例(90%)中,活检包括右侧额叶皮质、白质及上方软脑膜的全层切除。57%的活检具有诊断价值:最常见的诊断为阿尔茨海默病(18%)、克雅氏病(12%)和炎症性疾病(9%)。个别患者的其他诊断包括匹克病、皮质基底节变性和其他tau蛋白病、路易体痴呆、多发性硬化症、惠普尔病、进行性多灶性白质脑病、伴有皮质下缺血性白质脑病的大脑常染色体显性动脉病、血管病和副肿瘤性脑病。在非诊断组及整个系列中最常见的活检发现(37%)是非特异性胶质增生,其程度不一地累及皮质和白质。并发症发生率为11%,包括癫痫发作、颅内及伤口感染和颅内出血;未出现因该操作导致的死亡或持久性神经后遗症。在该系列过程中未发现诊断率或并发症发生率的趋势。活检获得的信息决定了11%患者的治疗方案。脑脊液细胞计数升高是活检时潜在可治疗(炎症性)过程的唯一可靠预测指标。行为改变、脑脊液蛋白升高以及脑脊液和血清中匹配的寡克隆带这一组合与活检时的非特异性胶质增生相关。该系列研究强调了脑活检在痴呆症诊断中的价值,并表明某些临床和实验室特征可能有助于指导在无法通过其他方法排除可治疗疾病时进行脑活检的决策。